4‐1BB transcriptomic expression patterns across malignancies: Implications for clinical trials of 4‐1BB agonists

Benzer Materyaller

• 4‐1BB transcriptomic expression patterns across malignancies: Implications for clinical trials of 4‐1BB agonists
  Yazar:: Yuji Uehara, ve diğerleri
  Baskı/Yayın Bilgisi: (2024-10-01)
• OX40 transcriptomic expression and its association with immune checkpoints and clinical outcomes
  Yazar:: Bicky Thapa, ve diğerleri
  Baskı/Yayın Bilgisi: (2026-07-01)
• The CD40 agonist HERA-CD40L results in enhanced activation of antigen presenting cells, promoting an anti-tumor effect alone and in combination with radiotherapy
  Yazar:: Jamie Frankish, ve diğerleri
  Baskı/Yayın Bilgisi: (2023-05-01)
• CD40- and CD95-specific antibody single chain-Baff fusion proteins display BaffR-, TACI- and BCMA-restricted agonism
  Yazar:: Johannes Nelke, ve diğerleri
  Baskı/Yayın Bilgisi: (2020-01-01)
• High indoleamine 2,3-dioxygenase transcript levels predict better outcome after front-line cancer immunotherapy
  Yazar:: Yu Fujiwara, ve diğerleri
  Baskı/Yayın Bilgisi: (2024-04-01)